Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$275.39+8.32 (+3.12%)
Close on Nov 13, 2026Market cap $17.07BP/E 22.4Yield –
Ascendis Pharma A/S cash
Cash and short-term investments held at the end of each period.
Ascendis Pharma A/S's cash was €812.26M at Jun 30, 2026. For fiscal 2025 it was €616.04M, up 10.1% from the year before. Over ten years it grew 17.8% a year on average. The highest annual figure on record is €616.04M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €616.04M | +10.1% |
| FY2024 | Dec 31, 2024 | €559.54M | +42.7% |
| FY2023 | Dec 31, 2023 | €392.16M | -11.8% |
| FY2022 | Dec 31, 2022 | €444.77M | -0.3% |
| FY2021 | Dec 31, 2021 | €446.27M | -23.7% |
| FY2020 | Dec 31, 2020 | €584.52M | -2.3% |
| FY2019 | Dec 31, 2019 | €598.11M | +115.3% |
| FY2018 | Dec 31, 2018 | €277.86M | +42.2% |
| FY2017 | Dec 31, 2017 | €195.35M | +8.3% |
| FY2016 | Dec 31, 2016 | €180.33M | +50.7% |
| FY2015 | Dec 31, 2015 | €119.65M | +138.5% |
| FY2014 | Dec 31, 2014 | €50.17M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €812.26M | +64.4% |
| Q1 FY2026 | Mar 31, 2026 | €572.82M | +10.6% |
| Q4 FY2025 | Dec 31, 2025 | €616.04M | +10.1% |
| Q3 FY2025 | Sep 30, 2025 | €539.09M | -13.8% |
| Q2 FY2025 | Jun 30, 2025 | €494.05M | +91.0% |
| Q1 FY2025 | Mar 31, 2025 | €517.92M | +61.7% |
| Q4 FY2024 | Dec 31, 2024 | €559.54M | +42.7% |
| Q3 FY2024 | Sep 30, 2024 | €625.52M | +41.8% |
| Q2 FY2024 | Jun 30, 2024 | €258.70M | -34.4% |
| Q1 FY2024 | Mar 31, 2024 | €320.24M | -36.1% |
| Q4 FY2023 | Dec 31, 2023 | €392.16M | -11.8% |
| Q3 FY2023 | Sep 30, 2023 | €441.27M | -27.5% |
| Q2 FY2023 | Jun 30, 2023 | €394.22M | -41.4% |
| Q1 FY2023 | Mar 31, 2023 | €501.28M | -33.7% |
| Q4 FY2022 | Dec 31, 2022 | €444.77M | -0.3% |
| Q3 FY2022 | Sep 30, 2022 | €608.33M | -12.2% |
| Q2 FY2022 | Jun 30, 2022 | €672.39M | +74.9% |
| Q1 FY2022 | Mar 31, 2022 | €755.64M | +52.6% |
| Q4 FY2021 | Dec 31, 2021 | €446.27M | -23.7% |
| Q3 FY2021 | Sep 30, 2021 | €692.94M | -9.2% |
| Q2 FY2021 | Jun 30, 2021 | €384.54M | +59.8% |
| Q1 FY2021 | Mar 31, 2021 | €495.05M | -7.4% |
| Q4 FY2020 | Dec 31, 2020 | €584.52M | -2.3% |
| Q3 FY2020 | Sep 30, 2020 | €763.45M | +15.9% |
| Q2 FY2020 | Jun 30, 2020 | €240.61M | -65.1% |
| Q1 FY2020 | Mar 31, 2020 | €534.38M | -23.3% |
| Q4 FY2019 | Dec 31, 2019 | €598.11M | +115.3% |
| Q3 FY2019 | Sep 30, 2019 | €658.66M | +112.2% |
| Q2 FY2019 | Jun 30, 2019 | €690.36M | +95.8% |
| Q1 FY2019 | Mar 31, 2019 | €696.66M | +100.0% |
| Q4 FY2018 | Dec 31, 2018 | €277.86M | +42.2% |
| Q3 FY2018 | Sep 30, 2018 | €310.33M | +50.4% |
| Q2 FY2018 | Jun 30, 2018 | €352.60M | +176.9% |
| Q1 FY2018 | Mar 31, 2018 | €348.41M | +121.0% |
| Q4 FY2017 | Dec 31, 2017 | €195.35M | +8.3% |
| Q3 FY2017 | Sep 30, 2017 | €206.29M | +72.4% |
| Q2 FY2017 | Jun 30, 2017 | €127.32M | – |
| Q1 FY2017 | Mar 31, 2017 | €157.65M | – |
| Q4 FY2016 | Dec 31, 2016 | €180.33M | – |
| Q4 FY2015 | Dec 31, 2015 | €119.65M | – |
See a number that looks wrong?